
Opinion|Videos|October 11, 2024
Older Adults, High-Risk Populations, and Severe Illness
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- Older adults, especially those with chronic heart or lung diseases, are at high risk for severe RSV illness.
- Severe RSV can result in hospitalization, long-term respiratory complications, and increased mortality in older adults.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the CDC’s recommendation for an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years at increased risk, and outlines the conditions that elevate the risk for severe illness, including the implications of severe illness, such as hospitalization, long-term effects, complications, comorbidities, and mortality, while also comparing how RSV infection affects older vs younger adults.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The CDC recommends an RSV vaccine for all adults aged 75 years and older and for adults aged 60 to 74 years who are at increased risk for severe RSV. What conditions put an individual at high risk for developing severe illness?
- Describe the implications of severe illness (ie, hospitalization, long-term effects, complications, comorbidities, mortality).
- How does RSV infection affect older vs younger adults?
Advertisement
Related to this article

Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.

Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.

Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.

Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.

At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.

RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.

ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5

